Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Effector Therapeutics Inc
(NQ:
EFTR
)
0.1800
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Effector Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
January 09, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Announces Reverse Stock Split
January 09, 2024
EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket
January 08, 2024
Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th....
Via
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study
December 08, 2023
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive...
Via
Benzinga
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
December 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
November 28, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
November 15, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
November 13, 2023
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 13, 2023
Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning!
Via
InvestorPlace
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
November 06, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
October 24, 2023
Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
3 Promising Biotech Stocks That Will Make Early Investors Rich
October 02, 2023
Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies.
Via
InvestorPlace
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
September 11, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates
August 24, 2023
HC Wainwright has initiated coverage on eFFECTOR Therapeutics Inc (NASDAQ: EFTR) with a Buy rating
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
August 24, 2023
Via
Benzinga
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 28, 2023
Via
Benzinga
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 28, 2023
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
Via
Benzinga
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
June 08, 2023
eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 07, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 06, 2023
Via
Benzinga
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 31, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 30, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.